{
  "meta": {
    "title": "11_Antiemetic_Prokinetic_Miscellaneous",
    "url": "https://brainandscalpel.vercel.app/11-antiemetic-prokinetic-miscellaneous-46f8f6d4.html",
    "scrapedAt": "2025-11-30T06:59:37.956Z"
  },
  "questions": [
    {
      "id": 55516,
      "choices": [
        {
          "id": 287238,
          "text": "Cisapride"
        },
        {
          "id": 287239,
          "text": "Domperidone"
        },
        {
          "id": 287240,
          "text": "Itopride"
        },
        {
          "id": 287241,
          "text": "Metoclopramide"
        }
      ],
      "text": "Prokinetic drug which is mainly metabolized by Flavin monooxygenases is",
      "unique_key": "Q8468029",
      "question_audio": null,
      "question_video": null,
      "map_id": 34119602,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Itopride Itopride is a prokinetic drug that primarily acts as a dopamine D2 receptor antagonist and also has acetylcholinesterase inhibitory properties, enhancing gastrointestinal (GI) motility. Unlike other prokinetic agents that undergo metabolism by the cytochrome P450 (CYP) enzyme system, itopride is primarily metabolized by flavin-containing monooxygenases (FMO), specifically FMO3. This metabolism pathway reduces the likelihood of drug-drug interactions commonly seen with CYP-metabolized drugs, making it a safer option for patients on multiple medications. Itopride is mainly used for functional dyspepsia and gastroesophageal reflux disease (GERD)-associated delayed gastric emptying. Incorrect Options: (A) Cisapride: Cisapride is a 5-HT4 receptor agonist that enhances acetylcholine release, thereby stimulating gastrointestinal motility. However, it is metabolized by CYP3A4, not flavin monooxygenases. Due to its QT prolongation and risk of fatal arrhythmias (torsades de pointes), its use is now highly restricted. (B) Domperidone: Domperidone is a dopamine D2 receptor antagonist used to increase gastric motility and relieve nausea and vomiting. It is metabolized primarily by the CYP3A4 enzyme, making it susceptible to drug interactions with CYP3A4 inhibitors. It does not undergo metabolism via flavin monooxygenases. (D) Metoclopramide: Metoclopramide is another dopamine D2 receptor antagonist that also has 5-HT4 agonist activity, enhancing gastrointestinal motility. It is mainly metabolized by CYP2D6, not flavin monooxygenases. Additionally, it crosses the blood-brain barrier (BBB), which can lead to extrapyramidal side effects (EPS) such as tardive dyskinesia with long-term use.",
      "correct_choice_id": 287240,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31916781700221643/31916781700221643.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31916781700221643/31916781700221643.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55517,
      "choices": [
        {
          "id": 287242,
          "text": "Metoclopramide prokinetic action is not attenuated by atropine"
        },
        {
          "id": 287243,
          "text": "Domperidone prokinetic action is attenuated by atropine"
        },
        {
          "id": 287244,
          "text": "Domperidone prokinetic action is not attenuated by atropine"
        },
        {
          "id": 287245,
          "text": "None of the above"
        }
      ],
      "text": "True statement about Prokinetic action of Domperidone and Metoclopramide is",
      "unique_key": "Q3371227",
      "question_audio": null,
      "question_video": null,
      "map_id": 34401110,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Domperidone prokinetic action is not attenuated by atropine Domperidone is a dopamine D2 receptor antagonist that works by blocking D2 receptors in the gastrointestinal (GI) tract, thereby enhancing acetylcholine release from the myenteric plexus. This leads to increased gastric motility and faster gastric emptying. Unlike metoclopramide, domperidone’s prokinetic effect is independent of cholinergic pathways, meaning that its action is not blocked by atropine, which is a muscarinic receptor antagonist. This makes domperidone a reliable prokinetic agent in conditions where cholinergic blockade might be a concern. Incorrect Options: (A) Metoclopramide prokinetic action is not attenuated by atropine: This statement is incorrect because metoclopramide acts through both dopamine D2 receptor antagonism and 5-HT4 receptor agonism, which enhances cholinergic activity in the GI tract. Since atropine blocks muscarinic receptors, it can partially attenuate the prokinetic effect of metoclopramide by inhibiting cholinergic stimulation of gastric motility. (B) Domperidone prokinetic action is attenuated by atropine: This is incorrect because domperidone's prokinetic activity does not depend on direct cholinergic stimulation, so atropine does not reduce its action. Unlike metoclopramide, domperidone does not act on 5-HT4 receptors and primarily affects dopaminergic pathways, making it resistant to atropine’s inhibitory effects. (D) None of the above: This is incorrect because option (C) is the correct statement, as domperidone’s prokinetic action remains unaffected by atropine.",
      "correct_choice_id": 287244,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71065301700221655/71065301700221655.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71065301700221655/71065301700221655.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55518,
      "choices": [
        {
          "id": 287246,
          "text": "Central D2 antagonism"
        },
        {
          "id": 287247,
          "text": "Peripheral D2 antagonism"
        },
        {
          "id": 287248,
          "text": "5-HT4 agonism"
        },
        {
          "id": 287249,
          "text": "Both B and C"
        }
      ],
      "text": "The prokinetic activity of metoclopramide is mainly because of",
      "unique_key": "Q1977830",
      "question_audio": null,
      "question_video": null,
      "map_id": 34368378,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both B and C (Peripheral D2 antagonism and 5-HT4 agonism) The prokinetic activity of metoclopramide is primarily due to its peripheral dopamine D2 receptor antagonism and 5-HT4 receptor agonism. Peripheral D2 antagonism: In the gastrointestinal (GI) tract, dopamine normally inhibits the release of acetylcholine, slowing gastric motility. By blocking D2 receptors, metoclopramide removes this inhibitory effect, leading to increased acetylcholine release, enhanced gastric motility, and faster gastric emptying. 5-HT4 agonism: Activation of 5-HT4 receptors further stimulates acetylcholine release from enteric neurons, promoting peristalsis and enhancing gastrointestinal motility. This effect makes metoclopramide useful in treating gastroparesis, GERD, and functional dyspepsia. Incorrect Options: (A) Central D2 antagonism: While metoclopramide does block central D2 receptors, this mechanism is primarily responsible for its antiemetic effect, not its prokinetic action. Central D2 antagonism in the chemoreceptor trigger zone (CTZ) helps prevent nausea and vomiting, but it does not directly contribute to gastrointestinal motility enhancement. (B) Peripheral D2 antagonism: Although peripheral D2 antagonism plays a crucial role in metoclopramide’s prokinetic action, it is not the only mechanism. The additional 5-HT4 agonism significantly enhances its prokinetic effects, making option D the more complete answer. (C) 5-HT4 agonism: While 5-HT4 receptor agonism contributes significantly to metoclopramide’s prokinetic activity, peripheral D2 antagonism is also essential. Since both mechanisms work together, option D is more accurate.",
      "correct_choice_id": 287249,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29125141700221664/29125141700221664.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29125141700221664/29125141700221664.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55519,
      "choices": [
        {
          "id": 287250,
          "text": "Alosetron"
        },
        {
          "id": 287251,
          "text": "Lubipristone"
        },
        {
          "id": 287252,
          "text": "Linaclotide"
        },
        {
          "id": 287253,
          "text": "Loxiglumide"
        }
      ],
      "text": "Following are drugs used for IBS-constipation predominant except",
      "unique_key": "Q8638624",
      "question_audio": null,
      "question_video": null,
      "map_id": 34114520,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Alosetron. Alosetron is a selective 5-HT3 receptor antagonist, which is primarily used for irritable bowel syndrome with diarrhea (IBS-D) rather than constipation-predominant IBS (IBS-C). It works by slowing colonic transit and reducing visceral pain, which is beneficial for patients with diarrhea-predominant symptoms but can worsen constipation. Due to its potential risk of severe constipation and ischemic colitis, its use is restricted to specific patient populations. Therefore, it is not a treatment for IBS-C, making it the correct answer. Explanation of Incorrect Options: (B) Lubiprostone: This drug is a chloride channel activator that promotes chloride secretion in the intestinal lumen, leading to increased intestinal fluid and improved motility. It is approved for IBS-C and chronic idiopathic constipation, making it a correct option for IBS-C management. (C) Linaclotide: Linaclotide is a guanylate cyclase-C (GC-C) agonist, which increases cyclic GMP levels, stimulating chloride and bicarbonate secretion into the intestinal lumen. This results in increased fluid secretion and bowel movements, effectively treating IBS-C. (D) Loxiglumide: Loxiglumide is a cholecystokinin (CCK) antagonist, which affects gastrointestinal motility and secretion. Though not a primary treatment for IBS-C, it has been studied for its potential role in modulating gut motility, distinguishing it from Alosetron, which is specific for IBS-D.",
      "correct_choice_id": 287250,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31478521700128929/31478521700128929.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31478521700128929/31478521700128929.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55520,
      "choices": [
        {
          "id": 287254,
          "text": "Metoclopramide"
        },
        {
          "id": 287255,
          "text": "Ondansetron"
        },
        {
          "id": 287256,
          "text": "Aprepitant"
        },
        {
          "id": 287257,
          "text": "Prochlorperazine"
        }
      ],
      "text": "A patient on cisplatin therapy develops intractable vomiting on the third day of treatment. Agent of choice for controlling this vomiting is",
      "unique_key": "Q5171019",
      "question_audio": null,
      "question_video": null,
      "map_id": 34088063,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Aprepitant. Cisplatin-induced vomiting is highly emetogenic and occurs in two phases: acute (within 24 hours) and delayed (after 24 hours, peaking at 48-72 hours). The intractable vomiting experienced on the third day of treatment suggests delayed chemotherapy-induced nausea and vomiting (CINV), which is primarily mediated by substance P and neurokinin-1 (NK-1) receptors. Aprepitant is an NK-1 receptor antagonist, specifically designed to prevent and control delayed CINV by blocking the action of substance P in the central nervous system. It is highly effective when combined with a 5-HT3 antagonist (such as ondansetron) and a corticosteroid (such as dexamethasone) for optimal antiemetic protection. This makes aprepitant the preferred agent for controlling delayed vomiting caused by cisplatin and other highly emetogenic chemotherapies. Incorrect Options: (A) Metoclopramide: This is incorrect because while metoclopramide is a D2 receptor antagonist with prokinetic and antiemetic properties, it is not the first-line treatment for delayed CINV. High doses of metoclopramide have been used in the past, but they are less effective than NK-1 antagonists like aprepitant and may cause extrapyramidal side effects (EPS), such as dystonia and akathisia. (B) Ondansetron: This is incorrect because ondansetron is a 5-HT3 receptor antagonist, which is highly effective for acute CINV (within the first 24 hours) but not as effective for delayed CINV. Since this patient is experiencing vomiting on the third day, ondansetron alone would not be the best choice. However, it is often used in combination with aprepitant and corticosteroids for optimal prevention. (D) Prochlorperazine: This is incorrect because prochlorperazine is a D2 antagonist that is primarily used for mild to moderate nausea and vomiting, such as that caused by motion sickness or migraine. It is not effective for severe or delayed CINV, and its use in chemotherapy-induced vomiting is limited.",
      "correct_choice_id": 287256,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16067761700129316/16067761700129316.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16067761700129316/16067761700129316.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55521,
      "choices": [
        {
          "id": 287258,
          "text": "Sodium alginate + aluminum hydroxide gel"
        },
        {
          "id": 287259,
          "text": "Mosapride"
        },
        {
          "id": 287260,
          "text": "Omeprazole"
        },
        {
          "id": 287261,
          "text": "Metoclopramide"
        }
      ],
      "text": "Indicate the drug which does not improve lower esophageal sphincter tone or prevent gastroesophageal reflux, but is used as the first line treatment of gastroesophageal reflux disease",
      "unique_key": "Q3701435",
      "question_audio": null,
      "question_video": null,
      "map_id": 34970346,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Omeprazole. Omeprazole is a proton pump inhibitor (PPI) that works by irreversibly inhibiting the H+/K+ ATPase (proton pump) in the gastric parietal cells, leading to a profound and long-lasting reduction in gastric acid secretion. Although it does not improve lower esophageal sphincter (LES) tone or prevent gastroesophageal reflux, it is the first-line treatment for gastroesophageal reflux disease (GERD) because it effectively reduces acid exposure in the esophagus, promoting mucosal healing and relieving symptoms. PPIs like omeprazole are superior to prokinetic drugs or antacids in healing erosive esophagitis and preventing complications such as Barrett’s esophagus or esophageal strictures. They are the most effective long-term therapy for GERD. Incorrect Options: (A) Sodium alginate + aluminum hydroxide gel: This is incorrect because sodium alginate forms a protective barrier (raft) on top of gastric contents, preventing reflux into the esophagus. Aluminum hydroxide acts as an antacid, neutralizing gastric acid. While this combination provides symptomatic relief, it does not reduce acid production like PPIs, making it less effective for long-term GERD management. (B) Mosapride: This is incorrect because mosapride is a prokinetic drug that enhances gastrointestinal motility by stimulating 5-HT4 receptors. It increases LES tone and improves gastric emptying, thereby helping to prevent gastroesophageal reflux. However, it is not the first-line treatment for GERD because it does not effectively reduce acid exposure like PPIs do. (D) Metoclopramide: This is incorrect because metoclopramide is a dopamine (D2) antagonist with prokinetic properties. It enhances LES tone and accelerates gastric emptying, which can help reduce reflux episodes. However, it has a limited role in GERD due to significant side effects, including extrapyramidal symptoms (EPS) and tardive dyskinesia, making it less favorable compared to PPIs.",
      "correct_choice_id": 287260,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48568401700129340/48568401700129340.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48568401700129340/48568401700129340.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55522,
      "choices": [
        {
          "id": 287262,
          "text": "Domperidone"
        },
        {
          "id": 287263,
          "text": "Metoclopramides"
        },
        {
          "id": 287264,
          "text": "Mosapride"
        },
        {
          "id": 287265,
          "text": "Cisapride"
        }
      ],
      "text": "Which of the following Prokinetic drugs has been implicated in causing serious ventricular arrhythmias, particularly in patients concurrently receiving erythromycin or ketoconazole?",
      "unique_key": "Q8281836",
      "question_audio": null,
      "question_video": null,
      "map_id": 34359917,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Cisapride. Cisapride is a prokinetic agent that enhances gastrointestinal motility by stimulating 5-HT4 receptors, promoting acetylcholine release in the enteric nervous system. However, its use has been associated with serious ventricular arrhythmias, including Torsades de Pointes, due to QT interval prolongation. This risk is significantly increased when cisapride is co-administered with CYP3A4 inhibitors such as erythromycin or ketoconazole, which reduce its metabolism, leading to higher plasma levels and increased cardiac toxicity. Due to these concerns, cisapride has been withdrawn or restricted in many countries. Incorrect Options: (A) Domperidone: This is incorrect because domperidone is a dopamine (D2) antagonist that acts mainly on the peripheral nervous system and has minimal penetration of the blood-brain barrier. While it has been linked to QT prolongation and cardiac arrhythmias in high doses, its risk is lower compared to cisapride. Unlike cisapride, it does not significantly interact with CYP3A4 inhibitors like erythromycin or ketoconazole. (B) Metoclopramide: This is incorrect because metoclopramide primarily acts as a D2 antagonist and a weak 5-HT4 agonist, exerting prokinetic effects in the upper gastrointestinal tract. Although it has side effects like extrapyramidal symptoms and tardive dyskinesia, it does not significantly prolong the QT interval or cause life-threatening ventricular arrhythmias like cisapride. (C) Mosapride: This is incorrect because mosapride is a selective 5-HT4 agonist with fewer cardiac side effects compared to cisapride. It does not significantly prolong the QT interval and is considered safer for use in patients with cardiovascular risks.",
      "correct_choice_id": 287265,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56373131700129354/56373131700129354.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56373131700129354/56373131700129354.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55523,
      "choices": [
        {
          "id": 287266,
          "text": "Serotonergic 5-HT4"
        },
        {
          "id": 287267,
          "text": "Serotonergic 5-HT3"
        },
        {
          "id": 287268,
          "text": "Muscarinic M"
        },
        {
          "id": 287269,
          "text": "Dopaminergic D2"
        }
      ],
      "text": "Activation of the following type of receptors present on myenteric neurons by metoclopramide is primarily responsible for the enhanced acetylcholine release and improving gastric motility",
      "unique_key": "Q5463971",
      "question_audio": null,
      "question_video": null,
      "map_id": 34595371,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Serotonergic 5-HT4 receptors. Metoclopramide enhances gastric motility primarily by stimulating 5-HT4 receptors on myenteric neurons, leading to increased acetylcholine (ACh) release in the gastrointestinal tract. This enhanced cholinergic activity results in improved peristalsis, accelerated gastric emptying, and increased lower esophageal sphincter (LES) tone, making metoclopramide an effective prokinetic agent. The 5-HT4 receptor agonistic activity of metoclopramide is responsible for its primary prokinetic effects, which benefit patients with gastroparesis and GERD (gastroesophageal reflux disease). Incorrect Options: (B) Serotonergic 5-HT3 receptors: This is incorrect because 5-HT3 receptors are involved in nausea and vomiting rather than in gastric motility. Metoclopramide actually acts as an antagonist at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) of the brain, reducing nausea and vomiting. However, its prokinetic effects are not mediated by 5-HT3 receptor activation. (C) Muscarinic (M) receptors: This is incorrect because metoclopramide does not directly act on muscarinic receptors. While acetylcholine release enhances gastrointestinal motility through muscarinic receptors on smooth muscles, metoclopramide itself does not directly bind to or stimulate muscarinic receptors. Instead, it facilitates acetylcholine release indirectly through 5-HT4 receptor activation. (D) Dopaminergic D2 receptors: This is incorrect because metoclopramide is a D2 receptor antagonist, and D2 receptor blockade contributes to its antiemetic effects in the CTZ. However, dopamine normally inhibits acetylcholine release in the gut, so D2 antagonism can promote ACh release, aiding in gastric motility. Despite this, the primary mechanism for enhancing ACh release remains 5-HT4 receptor activation, making (A) the correct answer.",
      "correct_choice_id": 287266,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28819521700129368/28819521700129368.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28819521700129368/28819521700129368.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55524,
      "choices": [
        {
          "id": 287270,
          "text": "Prochlorperazine"
        },
        {
          "id": 287271,
          "text": "Aprepitant"
        },
        {
          "id": 287272,
          "text": "Metoclopramide"
        },
        {
          "id": 287273,
          "text": "Ondansetron"
        }
      ],
      "text": "The most effective antiemetic for controlling cisplatin induced vomiting is",
      "unique_key": "Q2245170",
      "question_audio": null,
      "question_video": null,
      "map_id": 34259305,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ondansetron. Ondansetron is a 5-HT3 receptor antagonist, which makes it one of the most effective antiemetics for preventing and controlling chemotherapy-induced nausea and vomiting (CINV), particularly that caused by cisplatin. Cisplatin and other platinum-based chemotherapeutic agents induce vomiting by releasing serotonin (5-HT) from enterochromaffin cells in the gastrointestinal tract, which then stimulates 5-HT3 receptors in the gut and the chemoreceptor trigger zone (CTZ) in the brain. Ondansetron blocks these receptors, effectively preventing both acute-phase nausea and vomiting associated with cisplatin. Incorrect Options: (A) Prochlorperazine: This is incorrect because prochlorperazine is a dopamine (D2) receptor antagonist that is primarily used to treat nausea and vomiting of mild to moderate severity. It is not as effective as 5-HT3 antagonists like ondansetron for cisplatin-induced vomiting, which is primarily mediated by serotonin release. (B) Aprepitant: While aprepitant is an NK1 receptor antagonist and is effective for delayed-phase chemotherapy-induced nausea and vomiting (CINV), it is not the most effective drug for the acute-phase vomiting associated with cisplatin. It is often used in combination with ondansetron for optimal control of both acute and delayed CINV, but ondansetron alone is more effective in controlling the acute phase. (C) Metoclopramide: While metoclopramide has both D2 receptor antagonist and 5-HT4 agonist properties, it is less effective than ondansetron in controlling cisplatin-induced vomiting. High-dose metoclopramide was historically used before the advent of 5-HT4 antagonists, but it is now considered inferior and is associated with significant extrapyramidal side effects.",
      "correct_choice_id": 287273,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53338331700129381/53338331700129381.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53338331700129381/53338331700129381.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55525,
      "choices": [
        {
          "id": 287274,
          "text": "Domperidone"
        },
        {
          "id": 287275,
          "text": "Cisapride"
        },
        {
          "id": 287276,
          "text": "Metoclopramide"
        },
        {
          "id": 287277,
          "text": "Ondansetron"
        }
      ],
      "text": "Which antipeptic drug selectively blocks levodopa induced vomiting without blocking its anti-Parkinsonian action?",
      "unique_key": "Q2015555",
      "question_audio": null,
      "question_video": null,
      "map_id": 34611494,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Domperidone. Domperidone is a peripherally acting dopamine (D2) receptor antagonist that effectively prevents nausea and vomiting induced by levodopa without interfering with its anti-Parkinsonian action. Unlike metoclopramide, domperidone does not cross the blood-brain barrier significantly, so it does not block central dopamine receptors that are crucial for the therapeutic effects of levodopa in Parkinson’s disease. By acting mainly on the chemoreceptor trigger zone (CTZ) in the area postrema (which is outside the blood-brain barrier), domperidone selectively prevents nausea and vomiting without worsening Parkinsonian symptoms. Incorrect Options: (B) Cisapride: This is incorrect because cisapride is a prokinetic agent that enhances gastrointestinal motility by increasing acetylcholine release through 5-HT4 receptor agonism. It does not antagonize dopamine receptors and is not effective in preventing levodopa-induced vomiting. (C) Metoclopramide: Metoclopramide is a D2 receptor antagonist that can prevent levodopa-induced nausea and vomiting, but it crosses the blood-brain barrier and blocks central dopamine receptors as well. This leads to worsening of Parkinsonian symptoms, making it unsuitable for patients with Parkinson’s disease who are on levodopa therapy. (D) Ondansetron: Ondansetron is a 5-HT3 receptor antagonist that is primarily used for the prevention of nausea and vomiting due to chemotherapy, radiotherapy, or post-operative conditions. It does not target dopamine receptors and is not specifically effective against levodopa-induced vomiting.",
      "correct_choice_id": 287274,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49422731700129396/49422731700129396.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49422731700129396/49422731700129396.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55526,
      "choices": [
        {
          "id": 287278,
          "text": "Domperidone"
        },
        {
          "id": 287279,
          "text": "Cisapride"
        },
        {
          "id": 287280,
          "text": "Metoclopramide"
        },
        {
          "id": 287281,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following Prokinetic drugs produces extrapyramidal side effects?",
      "unique_key": "Q8730321",
      "question_audio": null,
      "question_video": null,
      "map_id": 34684276,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Metoclopramide. Metoclopramide is a dopamine (D2) receptor antagonist that crosses the blood-brain barrier and blocks dopamine receptors in the central nervous system (CNS). This can lead to extrapyramidal side effects (EPS), such as acute dystonia, tardive dyskinesia, and Parkinsonism-like symptoms. These adverse effects occur because dopamine plays a crucial role in modulating motor control in the basal ganglia, and its blockade disrupts normal movement regulation. EPS is more commonly seen in younger patients and with prolonged or high-dose use of metoclopramide. Incorrect Options: (A) Domperidone: Unlike metoclopramide, domperidone does not cross the blood-brain barrier significantly. It acts mainly on peripheral dopamine receptors in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ), which is outside the blood-brain barrier. Because it does not block central dopamine receptors, it does not cause extrapyramidal side effects. (B) Cisapride: Cisapride is a prokinetic agent that enhances gastrointestinal motility by stimulating 5-HT4 receptors and increasing acetylcholine release in the gut. It does not antagonize dopamine receptors and is not associated with extrapyramidal side effects. (D) All of the above: This is incorrect because only metoclopramide (not domperidone or cisapride) causes extrapyramidal side effects.",
      "correct_choice_id": 287280,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26531521700129412/26531521700129412.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26531521700129412/26531521700129412.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55527,
      "choices": [
        {
          "id": 287282,
          "text": "Increase lower esophageal sphincter tone"
        },
        {
          "id": 287283,
          "text": "Increase large intestinal peristalsis"
        },
        {
          "id": 287284,
          "text": "Increase gastric peristalsis"
        },
        {
          "id": 287285,
          "text": "Prokinetic action is blocked by atropine"
        }
      ],
      "text": "Metoclopramide has the following actions EXCEPT",
      "unique_key": "Q2677649",
      "question_audio": null,
      "question_video": null,
      "map_id": 34240627,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Increase large intestinal peristalsis. Metoclopramide is a prokinetic agent that primarily enhances upper gastrointestinal (GI) motility, particularly in the esophagus, stomach, and small intestine. However, it has minimal effects on large intestinal peristalsis. Its primary action is to promote gastric emptying and reduce reflux by increasing lower esophageal sphincter (LES) tone and stimulating gastric peristalsis. Since it does not significantly affect colonic motility, it is not used for constipation treatment or large bowel dysfunction. Incorrect Options: (A) Increase lower esophageal sphincter tone: Metoclopramide increases LES tone, reducing gastroesophageal reflux. It does so by blocking dopamine (D2) receptors and enhancing acetylcholine release in the myenteric plexus, which strengthens the sphincter and prevents reflux. (C) Increase gastric peristalsis: Metoclopramide promotes gastric emptying by increasing antral contractions and coordinating peristalsis in the stomach and duodenum. This makes it useful in conditions like gastroparesis and delayed gastric emptying. (D) Prokinetic action is blocked by atropine: Metoclopramide’s prokinetic effects are mediated by cholinergic mechanisms. Atropine, a muscarinic antagonist, blocks these cholinergic effects, thereby reducing metoclopramide-induced gastric motility enhancement.",
      "correct_choice_id": 287283,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48870751700129428/48870751700129428.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48870751700129428/48870751700129428.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55528,
      "choices": [
        {
          "id": 287286,
          "text": "Twelve hours before commencing journey"
        },
        {
          "id": 287287,
          "text": "At the first feeling of motion sickness"
        },
        {
          "id": 287288,
          "text": "Immediately after commencing journey"
        },
        {
          "id": 287289,
          "text": "One hour before commencing journey"
        }
      ],
      "text": "In case of hill journey, antimotion sickness drugs are best administered at……..",
      "unique_key": "Q4742619",
      "question_audio": null,
      "question_video": null,
      "map_id": 34574395,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) One hour before commencing journey. Antimotion sickness drugs, such as antihistamines (e.g., meclizine, promethazine) and anticholinergics (e.g., scopolamine), are most effective when taken at least one hour before travel. This allows the drug to be absorbed, reach peak plasma concentration, and exert its effect on the vestibular system, which is responsible for motion sickness. Once symptoms have developed, these drugs are less effective in controlling nausea and vomiting. Explanation of Incorrect Options: (A) Twelve hours before commencing journey: This is too early, as most antimotion sickness drugs have a duration of action between 6 to 12 hours. Taking them too far in advance may lead to diminished effects by the time motion sickness triggers occur. (B) At the first feeling of motion sickness: By the time symptoms start, the vestibular system is already overstimulated, making it difficult for the drugs to prevent symptoms effectively. Preventive administration is key to successful motion sickness management. (C) Immediately after commencing journey: While this timing might still offer some benefits, it does not allow enough time for drug absorption and peak action, making it less effective compared to preemptive dosing.",
      "correct_choice_id": 287289,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67005351700129444/67005351700129444.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67005351700129444/67005351700129444.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55529,
      "choices": [
        {
          "id": 287290,
          "text": "Secretion"
        },
        {
          "id": 287291,
          "text": "Motility"
        },
        {
          "id": 287292,
          "text": "Inflammation"
        },
        {
          "id": 287293,
          "text": "Digestion"
        }
      ],
      "text": "A 46-year-old male presents to OPD with diarrhea and abdominal pain. On investigations, it was found to be non-infective and you proceed with diphenoxylate therapy in this patient. Which of the following is the primary target for the drug you prescribed to this patient?",
      "unique_key": "Q7882867",
      "question_audio": null,
      "question_video": null,
      "map_id": 34884154,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Motility. Diphenoxylate is an opioid antidiarrheal agent that primarily acts on the mu-opioid receptors in the gut, leading to a decrease in intestinal motility. It works by prolonging the transit time of intestinal contents, allowing for greater absorption of water and electrolytes, which results in firmer stools. It is commonly used for non-infective diarrhea to reduce stool frequency and improve symptoms. Because diphenoxylate can cross the blood-brain barrier in high doses and cause central opioid effects, it is combined with atropine to discourage abuse. Explanation of Incorrect Options: (A) Secretion – Incorrect. Diphenoxylate does not significantly alter intestinal secretion of fluids or electrolytes. Other antidiarrheal agents, such as bismuth subsalicylate or racecadotril, have a more direct impact on reducing secretion in diarrheal conditions. (C) Inflammation – Incorrect. Diphenoxylate does not possess anti-inflammatory properties and does not target the underlying inflammation in conditions such as inflammatory bowel disease (IBD). For inflammatory diarrhea, drugs like 5-aminosalicylic acid (5-ASA) or corticosteroids are more appropriate. (D) Digestion – Incorrect. Diphenoxylate does not impact digestive enzyme activity or nutrient breakdown. It slows peristalsis but does not interfere with the digestive process itself. Enzyme replacement therapy (e.g., pancreatic enzyme supplements) would be needed for digestive insufficiencies.",
      "correct_choice_id": 287291,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49286781700132885/49286781700132885.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49286781700132885/49286781700132885.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55530,
      "choices": [
        {
          "id": 287294,
          "text": "Octreotide"
        },
        {
          "id": 287295,
          "text": "Loperamide"
        },
        {
          "id": 287296,
          "text": "Metronidazole"
        },
        {
          "id": 287297,
          "text": "Pancreatic lipase"
        }
      ],
      "text": "Aryan, a 14-year-old boy presented with chronic diarrhea and weight loss. History reveals that he has repeated attacks of respiratory tract infections with pseudomonas aeruginosa. His younger brother died from a severe respiratory infection at the age of 7. Which of the following agents is most likely to improve this patient’s condition?",
      "unique_key": "Q7031520",
      "question_audio": null,
      "question_video": null,
      "map_id": 34121107,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Pancreatic lipase. The clinical presentation of chronic diarrhea, weight loss, recurrent respiratory tract infections with Pseudomonas aeruginosa, and a family history of early childhood death due to respiratory illness strongly suggests cystic fibrosis (CF). Cystic fibrosis is a genetic disorder caused by mutations in the CFTR gene, leading to thick mucus production that affects multiple organs, primarily the lungs and gastrointestinal tract. One of the major complications of CF is pancreatic insufficiency, where the thick mucus blocks pancreatic ducts, preventing the secretion of digestive enzymes. This results in malabsorption of fats, proteins, and fat-soluble vitamins (A, D, E, K), leading to steatorrhea (fatty diarrhea) and weight loss. Pancreatic enzyme replacement therapy (PERT), including pancreatic lipase, is the cornerstone of treatment for malabsorption and chronic diarrhea in CF patients. It helps in digesting fats, carbohydrates, and proteins, thereby improving nutrient absorption, reducing diarrhea, and promoting weight gain. Explanation of Incorrect Options: (A) Octreotide – Incorrect. Octreotide is a somatostatin analog that reduces hormonal secretions and intestinal motility, primarily used for secretory diarrhea (e.g., carcinoid syndrome, VIPomas, short bowel syndrome, or chemotherapy-induced diarrhea). It does not address the underlying pancreatic enzyme deficiency in cystic fibrosis. (B) Loperamide – Incorrect. Loperamide is an opioid antidiarrheal that slows intestinal motility to reduce stool frequency. While it may temporarily reduce diarrhea, it does not correct fat malabsorption, which is the root cause of diarrhea in CF. In CF patients, loperamide use without pancreatic enzyme therapy may worsen bloating and malabsorption. (C) Metronidazole – Incorrect. Metronidazole is an antibiotic and antiprotozoal drug used to treat Clostridium difficile infections, bacterial overgrowth, and certain parasitic infections. While CF patients are prone to infections, metronidazole does not treat pancreatic insufficiency or improve nutrient absorption.",
      "correct_choice_id": 287297,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50866441700132899/50866441700132899.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50866441700132899/50866441700132899.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55531,
      "choices": [
        {
          "id": 287298,
          "text": "Mesalazine"
        },
        {
          "id": 287299,
          "text": "Sulfasalazine"
        },
        {
          "id": 287300,
          "text": "Prednisolone"
        },
        {
          "id": 287301,
          "text": "Vancomycin"
        }
      ],
      "text": "The preferred drug for controlling an acute exacerbation of ulcerative Colitis is",
      "unique_key": "Q6671059",
      "question_audio": null,
      "question_video": null,
      "map_id": 34094816,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Prednisolone. Prednisolone, a corticosteroid, is the preferred drug for controlling an acute exacerbation of ulcerative colitis (UC). Acute flares of UC involve severe inflammation of the colon, leading to symptoms such as bloody diarrhea, abdominal pain, fever, and weight loss. Glucocorticoids like prednisolone are highly effective in rapidly suppressing inflammation by inhibiting cytokine production, reducing immune cell infiltration, and stabilizing cell membranes. In moderate-to-severe UC exacerbations, prednisolone is typically administered orally or intravenously (IV in severe cases) to rapidly control symptoms and induce remission. However, due to significant side effects (osteoporosis, hyperglycemia, adrenal suppression), steroids are not used for long-term maintenance therapy and are tapered once remission is achieved. Explanation of Incorrect Options: (A) Mesalazine – Incorrect. Mesalazine (5-aminosalicylic acid, 5-ASA) is a first-line drug for mild-to-moderate UC and is used for maintenance of remission. However, it is not potent enough to control acute exacerbations of moderate-to-severe UC, where steroids are required. (B) Sulfasalazine – Incorrect. Sulfasalazine, another 5-ASA drug, is used in mild-to-moderate UC but is less preferred than mesalazine due to its higher risk of side effects (e.g., headache, nausea, hemolysis, hypersensitivity). It is not sufficient for acute flares, which require corticosteroids. (D) Vancomycin – Incorrect. Vancomycin is an antibiotic used for Clostridium difficile-associated diarrhea (CDI), not for UC exacerbations. UC is an inflammatory disease, not primarily an infection, so antibiotics do not play a major role in its treatment unless there is a secondary bacterial infection.",
      "correct_choice_id": 287300,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58769651700132968/58769651700132968.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58769651700132968/58769651700132968.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55532,
      "choices": [
        {
          "id": 287302,
          "text": "Docusate"
        },
        {
          "id": 287303,
          "text": "Loperamide"
        },
        {
          "id": 287304,
          "text": "Metoclopramide"
        },
        {
          "id": 287305,
          "text": "Sucralfate"
        }
      ],
      "text": "A 55-year-old woman with insulin-dependent diabetes of 40 years' duration complains of severe bloating and abdominal distress, especially after meals. Evaluation is consistent with diabetic gastroparesis. The drug you would be most likely to recommend is",
      "unique_key": "Q1485257",
      "question_audio": null,
      "question_video": null,
      "map_id": 34536278,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Metoclopramide. Explanation for the Correct Answer: Metoclopramide is the drug of choice for diabetic gastroparesis, a condition characterized by delayed gastric emptying due to autonomic neuropathy affecting the stomach. It works as a prokinetic agent by: Dopamine D2 receptor antagonism – This enhances gastric motility and promotes gastric emptying by removing dopamine’s inhibitory effect on gastrointestinal smooth muscle. 5-HT1 receptor agonism – This further enhances peristalsis and improves symptoms of bloating, nausea, and postprandial discomfort. 5-HT3 receptor antagonism – Provides an additional antiemetic effect, useful for nausea associated with gastroparesis. Since this 55-year-old diabetic woman has had long-standing insulin-dependent diabetes (40 years), her symptoms of severe bloating and abdominal distress after meals strongly suggest diabetic gastroparesis, making metoclopramide the best choice to relieve her symptoms. Incorrect Answers: A) Docusate: Docusate is a stool softener used to treat constipation by increasing water penetration into stool, making it easier to pass. It has no prokinetic properties and does not help with gastric emptying, making it ineffective for diabetic gastroparesis. B) Loperamide: Loperamide is an opioid agonist used to treat diarrhea by reducing intestinal motility. In gastroparesis, motility is already impaired, and loperamide would worsen symptoms by further slowing gastric emptying, making it contraindicated in this condition. D) Sucralfate: Sucralfate is a mucosal protective agent used in peptic ulcer disease (PUD). It forms a protective barrier over ulcers but does not affect gastric motility. Since this patient has gastroparesis, not an ulcer, sucralfate is not an appropriate treatment.",
      "correct_choice_id": 287304,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44410771700305569/44410771700305569.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44410771700305569/44410771700305569.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55533,
      "choices": [
        {
          "id": 287306,
          "text": "Aprepitant"
        },
        {
          "id": 287307,
          "text": "Domperidone"
        },
        {
          "id": 287308,
          "text": "Cisapride"
        },
        {
          "id": 287309,
          "text": "Metoclopramide"
        }
      ],
      "text": "A 3 year old child comes to emergency with vomiting. Nurse posted in emergency gives antiemetic to baby which is generally gives to adult patient. After few hours of hospital stay, child vomiting is stopped but child body gone into spasm with high tone in leg and neck muscles. Which antiemetic that nurse might have given to baby leading to above complication ?",
      "unique_key": "Q3350925",
      "question_audio": null,
      "question_video": null,
      "map_id": 34316517,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Metoclopramide Explanation for the Correct Answer: Metoclopramide is a dopamine D2 receptor antagonist used as an antiemetic and prokinetic agent. In children, particularly those under 5 years of age, metoclopramide can cause extrapyramidal side effects (EPS) such as acute dystonia, opisthotonus (severe spasm with arching of the back), and oculogyric crisis (involuntary upward deviation of the eyes). Young children are more susceptible to these effects because their dopaminergic system is still developing, making them more prone to dopamine blockade-related complications. Dystonic reactions occur due to excessive dopamine inhibition in the basal ganglia, leading to abnormal muscle contractions and posturing. Symptoms can be treated with diphenhydramine or benztropine, which are anticholinergic drugs that counteract extrapyramidal symptoms. Due to the high risk of EPS, metoclopramide should be avoided in young children, and safer alternatives like ondansetron (a 5-HT3 antagonist) should be used instead. Explanation for the Incorrect Answers: (A) Aprepitant Incorrect because aprepitant is a neurokinin-1 (NK-1) receptor antagonist, primarily used for chemotherapy-induced nausea and vomiting (CINV). It does not cause extrapyramidal symptoms (EPS) and is rarely used in pediatric emergency settings. (B) Domperidone Incorrect because domperidone is a peripheral dopamine D2 receptor antagonist, meaning it does not cross the blood-brain barrier significantly. Since it has minimal central nervous system (CNS) effects, it is less likely to cause EPS compared to metoclopramide. However, it is not recommended for infants due to cardiac risks (QT prolongation and arrhythmias). (C) Cisapride Incorrect because cisapride is a serotonin 5-HT3 receptor agonist, used to enhance gastrointestinal motility. It does not block dopamine receptors, meaning it does not cause extrapyramidal symptoms. However, cisapride is not commonly used due to its association with QT prolongation and cardiac arrhythmias.",
      "correct_choice_id": 287309,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31355651700306052/31355651700306052.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31355651700306052/31355651700306052.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55534,
      "choices": [
        {
          "id": 287310,
          "text": "Constipation"
        },
        {
          "id": 287311,
          "text": "Diarrhea"
        },
        {
          "id": 287312,
          "text": "Headache"
        },
        {
          "id": 287313,
          "text": "Impotence"
        }
      ],
      "text": "A 27-year-old man complains of occasional heartburn. His physician makes a few suggestions of diet and lifestyle changes he could make as well as some medications he can take for symptom management. The patient decides to try a magnesium hydroxide (MgOH) preparation. Which of the following is a side effect of MgOH that the physician should warn him about?",
      "unique_key": "Q8142187",
      "question_audio": null,
      "question_video": null,
      "map_id": 34063338,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Diarrhea. Magnesium hydroxide (MgOH) is an antacid commonly used to neutralize stomach acid and provide relief from heartburn, acid reflux, and indigestion. However, magnesium salts have an osmotic laxative effect, drawing water into the intestines and increasing gut motility. This can lead to diarrhea, which is a well-known side effect of magnesium-based antacids. Physicians often warn patients about diarrhea when prescribing or recommending magnesium-based medications. In some cases, magnesium-containing antacids are combined with aluminum hydroxide to counteract this effect, as aluminum can cause constipation. Explanation of Incorrect Options: (A) Constipation Incorrect because magnesium hydroxide actually causes diarrhea, not constipation. Aluminum hydroxide-based antacids (e.g., aluminum hydroxide) are more likely to cause constipation. (C) Headache Incorrect because headaches are not a typical side effect of magnesium hydroxide. Some gastrointestinal medications like proton pump inhibitors (PPIs) (e.g., omeprazole) can cause headaches, but MgOH does not. (D) Impotence Incorrect because magnesium hydroxide has no known effects on sexual function. Cimetidine (an H2 blocker) has anti-androgenic effects and may cause impotence, but MgOH does not.",
      "correct_choice_id": 287311,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10617781700305846/10617781700305846.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10617781700305846/10617781700305846.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55535,
      "choices": [
        {
          "id": 287314,
          "text": "Histamine H1 receptor"
        },
        {
          "id": 287315,
          "text": "Serotonin 5HT3 receptor"
        },
        {
          "id": 287316,
          "text": "Dopamine D2 receptor"
        },
        {
          "id": 287317,
          "text": "Opioid receptor"
        }
      ],
      "text": "Most important receptor involved in chemotherapy induced vomiting is",
      "unique_key": "Q4778075",
      "question_audio": null,
      "question_video": null,
      "map_id": 34572981,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Serotonin 5-HT3 Receptor The 5-HT3 receptor plays a crucial role in chemotherapy-induced vomiting. Chemotherapeutic agents damage enterochromaffin cells in the gastrointestinal (GI) tract, leading to the release of serotonin (5-HT). This serotonin activates 5-HT3 receptors in the vagal afferents, which transmit signals to the vomiting center and chemoreceptor trigger zone (CTZ) in the medulla, resulting in nausea and vomiting. This is why 5-HT3 receptor antagonists like ondansetron, granisetron, and palonosetron are the most effective drugs for preventing chemotherapy-induced nausea and vomiting (CINV). Incorrect Options: (A) Histamine H1 Receptor: The H1 receptor is primarily involved in motion sickness and vestibular-induced nausea rather than chemotherapy-induced vomiting. Antihistamines like promethazine and diphenhydramine are effective for motion sickness, but they are not the first-line treatment for CINV. (C) Dopamine D2 Receptor: The D2 receptor is involved in nausea and vomiting, particularly in the chemoreceptor trigger zone (CTZ). D2 antagonists like metoclopramide and domperidone are used to manage vomiting, but they are less effective than 5-HT4 antagonists for chemotherapy-induced nausea and vomiting. (D) Opioid Receptor: Opioid receptors, especially μ-opioid receptors, play a role in opioid-induced nausea and vomiting but are not the primary mediators of chemotherapy-induced vomiting. Opioid antagonists like naloxone are not used for CINV.",
      "correct_choice_id": 287315,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55536,
      "choices": [
        {
          "id": 287318,
          "text": "Lipase"
        },
        {
          "id": 287319,
          "text": "Amylase"
        },
        {
          "id": 287320,
          "text": "Trypsin"
        },
        {
          "id": 287321,
          "text": "All of the above"
        }
      ],
      "text": "A 60-year-old male with a history of chronic pancreatitis is experiencing steatorrhea and significant weight loss. His physician prescribes a pancreatic enzyme replacement therapy. Which of the following is a key component of this therapy?",
      "unique_key": "Q7977599",
      "question_audio": null,
      "question_video": null,
      "map_id": 34808117,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Pancreatic enzyme replacement therapy (PERT) is essential for patients with chronic pancreatitis, as the disease leads to exocrine pancreatic insufficiency (EPI), resulting in malabsorption, steatorrhea (fatty stools), and weight loss. PERT contains a combination of key digestive enzymes, including: Lipase – Essential for fat digestion. It breaks down triglycerides into monoglycerides and free fatty acids. This is crucial because steatorrhea primarily results from fat malabsorption. Amylase – Responsible for carbohydrate digestion, breaking down starches into simple sugars. Trypsin (Protease) – Helps in protein digestion by breaking proteins into smaller peptides and amino acids. Because pancreatic insufficiency affects the digestion of fats, proteins, and carbohydrates, PERT must contain all three enzymes to ensure complete digestion and nutrient absorption, making option (D) the correct choice. Explanation of Incorrect Options: (A) Lipase – Incorrect (Partially Correct). While lipase is the most important enzyme for fat digestion, pancreatic insufficiency also leads to poor digestion of proteins and carbohydrates. Using only lipase would not be sufficient to correct all malabsorption issues. (B) Amylase – Incorrect (Partially Correct). Amylase aids carbohydrate digestion, but fat and protein digestion also need to be addressed in patients with chronic pancreatitis. A therapy including only amylase would not correct steatorrhea or protein malabsorption. (C) Trypsin – Incorrect (Partially Correct). Trypsin (a protease) is critical for protein digestion, but since steatorrhea is primarily due to fat malabsorption, lipase is more important. A therapy containing only trypsin would not treat fat or carbohydrate malabsorption effectively.",
      "correct_choice_id": 287321,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55537,
      "choices": [
        {
          "id": 287322,
          "text": "Inhibition of calcium absorption"
        },
        {
          "id": 287323,
          "text": "Increased gastric acid production"
        },
        {
          "id": 287324,
          "text": "Alteration of gut flora"
        },
        {
          "id": 287325,
          "text": "Impairment of vitamin B12 absorption"
        }
      ],
      "text": "A patient with GERD has been taking omeprazole for six months and now presents with new onset of wrist fractures. Which of the following is a potential mechanism for this adverse effect?",
      "unique_key": "Q5627350",
      "question_audio": null,
      "question_video": null,
      "map_id": 34753316,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Inhibition of calcium absorption. Proton pump inhibitors (PPIs) like omeprazole reduce gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in parietal cells. Gastric acid is essential for solubilizing dietary calcium, particularly calcium carbonate, to facilitate absorption in the intestines. Long-term PPI use leads to reduced calcium absorption, increasing the risk of osteopenia, osteoporosis, and fractures, particularly in weight-bearing bones like the wrist, spine, and hip. Several studies have shown that chronic PPI use is associated with an increased risk of fractures, especially in older adults or those with other risk factors for osteoporosis. Calcium citrate, which does not require stomach acid for absorption, may be a better supplement option for patients on chronic PPI therapy. Explanation of Incorrect Options: (B) Increased gastric acid production – Incorrect. PPIs block acid secretion, rather than increasing it. Although rebound acid hypersecretion can occur after discontinuing PPIs, it does not explain chronic calcium malabsorption leading to fractures. (C) Alteration of gut flora – Incorrect. PPIs alter gut microbiota, which can increase susceptibility to Clostridium difficile infection and small intestinal bacterial overgrowth (SIBO), but this does not directly lead to fractures. The primary mechanism for fractures is impaired calcium absorption, not microbiota changes. (D) Impairment of vitamin B12 absorption – Incorrect. Long-term PPI use can lead to B12 deficiency due to reduced release of intrinsic factor, but B12 deficiency primarily causes neurological symptoms (e.g., neuropathy, cognitive impairment, megaloblastic anemia), not fractures. Calcium malabsorption, not B12 deficiency, is the main cause of bone weakening in PPI users.",
      "correct_choice_id": 287322,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55538,
      "choices": [
        {
          "id": 287326,
          "text": "Anti-TNF agents"
        },
        {
          "id": 287327,
          "text": "5-ASA compounds"
        },
        {
          "id": 287328,
          "text": "Corticosteroids"
        },
        {
          "id": 287329,
          "text": "Antibiotics"
        }
      ],
      "text": "A 40-year-old male with a history of inflammatory bowel disease is experiencing frequent episodes of abdominal pain and diarrhea. His physician considers prescribing a biologic therapy. Which of the following classes of drugs is typically used in this context?",
      "unique_key": "Q8514980",
      "question_audio": null,
      "question_video": null,
      "map_id": 34971642,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Anti-TNF agents. Tumor Necrosis Factor (TNF) inhibitors are biologic therapies commonly used in moderate to severe inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. These drugs target TNF-?, a key inflammatory cytokine involved in the pathogenesis of IBD, thereby reducing inflammation, controlling symptoms, and promoting mucosal healing. Common anti-TNF agents used in IBD include: Infliximab – A monoclonal antibody used in both ulcerative colitis and Crohn’s disease, particularly in steroid-refractory cases. Adalimumab – A fully human monoclonal antibody, often used as a long-term treatment for Crohn’s disease and ulcerative colitis. Certolizumab – Used primarily in Crohn’s disease. Anti-TNF agents are especially beneficial for patients with frequent relapses, steroid dependence, or complications such as fistulas. Explanation of Incorrect Options: (B) 5-ASA compounds – Incorrect. 5-Aminosalicylic acid (5-ASA) drugs such as mesalazine and sulfasalazine are first-line therapies for mild to moderate ulcerative colitis, but they are not biologic agents. They work by reducing local inflammation in the gut, but they are not effective in severe cases or Crohn’s disease. (C) Corticosteroids – Incorrect. Corticosteroids (e.g., prednisolone, budesonide) are used for acute flares of IBD but are not suitable for long-term maintenance due to severe side effects (e.g., osteoporosis, hyperglycemia, adrenal suppression). Biologic therapy (e.g., anti-TNF agents) is preferred for chronic disease management. (D) Antibiotics – Incorrect. Antibiotics (e.g., metronidazole, ciprofloxacin) are sometimes used in IBD, particularly for Crohn’s disease with fistulas or abscesses, but they are not the primary treatment for chronic IBD. They do not directly modulate the immune system like biologics do.",
      "correct_choice_id": 287326,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55539,
      "choices": [
        {
          "id": 287330,
          "text": "Inhibition of aldosterone"
        },
        {
          "id": 287331,
          "text": "Potassium retention"
        },
        {
          "id": 287332,
          "text": "Diuresis"
        },
        {
          "id": 287333,
          "text": "All of the above"
        }
      ],
      "text": "A 50-year-old male with a history of liver cirrhosis presents with ascites. He is started on spironolactone. Which of the following is a significant pharmacological effect of spironolactone that benefits this patient?",
      "unique_key": "Q9538752",
      "question_audio": null,
      "question_video": null,
      "map_id": 34506044,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Spironolactone is a potassium-sparing diuretic and an aldosterone antagonist that is highly effective in the management of ascites due to liver cirrhosis. It exerts multiple beneficial pharmacological effects: Inhibition of Aldosterone: Spironolactone blocks aldosterone receptors in the distal tubules of the nephron, reducing sodium and water retention. This is crucial in cirrhosis, where hyperaldosteronism contributes to fluid overload and ascites formation. Potassium Retention: Unlike loop and thiazide diuretics, which cause potassium loss, spironolactone spares potassium by inhibiting aldosterone-mediated potassium excretion. This is beneficial in cirrhotic patients, who are prone to hypokalemia due to excessive aldosterone activity. Diuresis: Spironolactone promotes diuresis (increased urine production) by reducing sodium reabsorption. This helps mobilize ascitic fluid, decreasing abdominal distension and discomfort. Since spironolactone exerts all three effects—aldosterone inhibition, potassium retention, and diuresis—it is the preferred first-line treatment for cirrhotic ascites, making (D) the correct answer. Explanation of Incorrect Options: (A) Inhibition of Aldosterone – Partially Correct: While aldosterone inhibition is a key effect of spironolactone, it is not the only effect. Diuresis and potassium retention also contribute to its therapeutic benefit in ascites. (B) Potassium Retention – Partially Correct: Potassium retention helps prevent hypokalemia, a common complication of diuretic therapy, but alone it does not fully explain spironolactone’s effectiveness in managing ascites. (C) Diuresis – Partially Correct: Diuresis helps in fluid removal, but spironolactone's ability to counteract hyperaldosteronism is what makes it especially effective in cirrhotic patients.",
      "correct_choice_id": 287333,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55540,
      "choices": [
        {
          "id": 287334,
          "text": "Inhibiting intestinal motility"
        },
        {
          "id": 287335,
          "text": "Inhibiting water absorption in the intestines"
        },
        {
          "id": 287336,
          "text": "Binding to opioid receptors in the gut"
        },
        {
          "id": 287337,
          "text": "Enhancing mucus secretion"
        }
      ],
      "text": "A 40-year-old man with chronic diarrhea is diagnosed with an infectious cause. His physician decides to prescribe loperamide. Which of the following best describes the mechanism of action of loperamide?",
      "unique_key": "Q6065575",
      "question_audio": null,
      "question_video": null,
      "map_id": 34613253,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Binding to opioid receptors in the gut. Loperamide is an opioid receptor agonist that acts primarily on the ?-opioid receptors in the intestinal wall. By binding to these receptors, it reduces peristalsis and intestinal motility, thereby increasing the transit time of stool and allowing for greater absorption of water and electrolytes. This leads to a reduction in diarrheal symptoms. Importantly, loperamide does not cross the blood-brain barrier in significant amounts, so it lacks the central nervous system effects typically seen with other opioids. Incorrect Options: (A) Inhibiting intestinal motility – Partially Correct While loperamide does slow intestinal motility, this effect is mediated through opioid receptor activation, rather than directly inhibiting motility. The direct mechanism involves binding to ?-opioid receptors, making option (C) the more accurate answer. (B) Inhibiting water absorption in the intestines – Incorrect Loperamide actually promotes water absorption by increasing the time available for fluid reabsorption as stool moves more slowly through the intestines. Inhibiting water absorption would worsen diarrhea rather than treating it. (D) Enhancing mucus secretion – Incorrect Loperamide does not enhance mucus secretion. Its primary effect is reducing intestinal motility to decrease stool frequency and improve stool consistency.",
      "correct_choice_id": 287336,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55541,
      "choices": [
        {
          "id": 287338,
          "text": "Antibiotic action"
        },
        {
          "id": 287339,
          "text": "Mucosal protection"
        },
        {
          "id": 287340,
          "text": "Acid suppression"
        },
        {
          "id": 287341,
          "text": "Promoting gastric emptying"
        }
      ],
      "text": "A 28-year-old female is diagnosed with a peptic ulcer caused by Helicobacter pylori and is started on a quadruple therapy regimen that includes a PPI, bismuth subsalicylate, tetracycline, and metronidazole. What is the role of bismuth subsalicylate in this therapy?",
      "unique_key": "Q8279626",
      "question_audio": null,
      "question_video": null,
      "map_id": 34841995,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Mucosal protection. Bismuth subsalicylate plays a crucial role in quadruple therapy for Helicobacter pylori-induced peptic ulcers by coating the gastric mucosa and providing a protective barrier against stomach acid and bacterial toxins. Additionally, bismuth has mild antibacterial properties that help suppress H. pylori, though its primary role is protecting the ulcerated mucosa and enhancing healing. It also binds to ulcer craters, preventing further irritation and allowing for tissue regeneration. Explanation of Incorrect Options: (A) Antibiotic action – Incorrect While bismuth has some mild antibacterial activity against H. pylori, it is not classified as an antibiotic. The primary antibiotics in quadruple therapy are tetracycline and metronidazole, which directly target H. pylori. Thus, bismuth’s main function is mucosal protection rather than direct antibiotic action. (C) Acid suppression – Incorrect Bismuth does not suppress acid production. In quadruple therapy, proton pump inhibitors (PPIs) such as omeprazole or lansoprazole are used for acid suppression, which is essential to enhance the effectiveness of antibiotics. (D) Promoting gastric emptying – Incorrect Bismuth does not have a prokinetic effect and does not influence gastric motility. Medications like metoclopramide or domperidone are used for promoting gastric emptying, but these are not part of standard H. pylori therapy.",
      "correct_choice_id": 287339,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55542,
      "choices": [
        {
          "id": 287342,
          "text": "Nephrotoxicity"
        },
        {
          "id": 287343,
          "text": "Nausea"
        },
        {
          "id": 287344,
          "text": "Pancreatitis"
        },
        {
          "id": 287345,
          "text": "Myelosuppression"
        }
      ],
      "text": "A 35-year-old woman with a history of ulcerative colitis is being treated with mesalamine. Which of the following is a common side effect associated with this medication?",
      "unique_key": "Q2400462",
      "question_audio": null,
      "question_video": null,
      "map_id": 34651703,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Nausea. Mesalamine (5-aminosalicylic acid or 5-ASA) is an anti-inflammatory drug commonly used in the treatment of ulcerative colitis (UC). It works by inhibiting cyclooxygenase and lipoxygenase pathways, thereby reducing the production of pro-inflammatory prostaglandins and leukotrienes in the intestinal mucosa. This helps control inflammation and symptoms of UC. One of the most common side effects of mesalamine is gastrointestinal discomfort, including nausea, vomiting, abdominal pain, and diarrhea. These symptoms are often mild and can be managed by taking the medication with food. Explanation of Incorrect Options: (A) Nephrotoxicity – Incorrect Although mesalamine has been associated with interstitial nephritis and renal impairment, this is a rare adverse effect rather than a common one. Regular renal function monitoring (creatinine, BUN) is recommended in patients on long-term therapy. (C) Pancreatitis – Incorrect Acute pancreatitis is a rare but possible side effect of mesalamine. However, it is not among the most common adverse effects. Patients with unexplained abdominal pain and elevated pancreatic enzymes should be evaluated for drug-induced pancreatitis. (D) Myelosuppression – Incorrect Mesalamine does not typically cause myelosuppression. Myelosuppression is more commonly associated with immunosuppressive drugs like azathioprine and methotrexate, which may be used in severe UC cases.",
      "correct_choice_id": 287343,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55543,
      "choices": [
        {
          "id": 287346,
          "text": "Dicyclomine"
        },
        {
          "id": 287347,
          "text": "Loperamide"
        },
        {
          "id": 287348,
          "text": "Alosetron"
        },
        {
          "id": 287349,
          "text": "Rifaximin"
        }
      ],
      "text": "A 32-year-old female presents with recurrent abdominal pain and altered bowel habits, diagnosed as IBS with predominant diarrhea. Which of the following medications might be prescribed to help manage her symptoms?",
      "unique_key": "Q7970003",
      "question_audio": null,
      "question_video": null,
      "map_id": 34854625,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Alosetron. Alosetron is a selective serotonin 5-HT? receptor antagonist that is specifically used for the treatment of irritable bowel syndrome (IBS) with predominant diarrhea (IBS-D) in women who have severe symptoms that have not responded to other treatments. By blocking 5-HT? receptors in the gut, alosetron reduces visceral pain, decreases colonic motility, and increases colonic transit time, leading to improved symptoms of diarrhea and abdominal pain in IBS-D patients. Alosetron is only approved for use in women with severe IBS-D, as studies have shown a greater benefit in female patients. However, due to the risk of ischemic colitis and severe constipation, its use is restricted and should be reserved for patients with refractory symptoms under close medical supervision. Explanation of Incorrect Options: (A) Dicyclomine – Incorrect Dicyclomine is an antispasmodic agent (anticholinergic) used to relieve abdominal pain and cramping in IBS, but it does not specifically target diarrhea. It may be useful in IBS with predominant pain, but it does not effectively manage diarrhea symptoms in IBS-D. (B) Loperamide – Incorrect Loperamide is an opioid receptor agonist that slows intestinal motility and reduces stool frequency, making it useful in treating diarrhea. However, it does not address the abdominal pain component of IBS-D and is not approved specifically for IBS-D treatment. It may provide symptomatic relief but lacks the central pain-modulating effects of alosetron. (D) Rifaximin – Incorrect Rifaximin is a non-absorbable antibiotic that is used to treat small intestinal bacterial overgrowth (SIBO) and traveler’s diarrhea. While it has been approved for IBS-D, its primary action is altering gut microbiota, and it is typically reserved for IBS-D patients with suspected bacterial overgrowth. Alosetron remains the preferred choice for severe, refractory IBS-D in women.",
      "correct_choice_id": 287348,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55544,
      "choices": [
        {
          "id": 287350,
          "text": "Osteoporosis"
        },
        {
          "id": 287351,
          "text": "Neutropenia"
        },
        {
          "id": 287352,
          "text": "Hyperkalemia"
        },
        {
          "id": 287353,
          "text": "Allergic reactions"
        }
      ],
      "text": "A 45-year-old male with Crohn's disease presents with worsening abdominal pain and diarrhea despite being on mesalamine. The physician considers adding a corticosteroid to his treatment plan. Which of the following is a potential concern with long-term corticosteroid use?",
      "unique_key": "Q1663925",
      "question_audio": null,
      "question_video": null,
      "map_id": 34393786,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Osteoporosis. Corticosteroids, such as prednisone and budesonide, are commonly used in moderate to severe flare-ups of Crohn’s disease due to their potent anti-inflammatory effects. However, long-term corticosteroid use is associated with several significant adverse effects, including osteoporosis, which occurs due to inhibition of bone formation, increased bone resorption, and reduced calcium absorption. Chronic corticosteroid therapy can lead to decreased bone mineral density (BMD), increasing the risk of fractures, particularly in weight-bearing bones such as the vertebrae and hips. Due to this risk, corticosteroids are not recommended for long-term maintenance therapy in Crohn’s disease. Instead, immunomodulators (e.g., azathioprine, methotrexate) or biologics (e.g., anti-TNF agents) are preferred for long-term disease control. Patients on corticosteroids for prolonged periods should undergo bone density monitoring and may require calcium, vitamin D, or bisphosphonates to reduce the risk of osteoporosis. Explanation of Incorrect Options: (B) Neutropenia – Incorrect Corticosteroids generally cause leukocytosis (increase in white blood cell count) rather than neutropenia. They suppress inflammation and immune responses but do not typically lead to a reduction in neutrophils. (C) Hyperkalemia – Incorrect Corticosteroids are more commonly associated with hypokalemia (low potassium levels) rather than hyperkalemia. This occurs due to increased renal excretion of potassium, especially with mineralocorticoid activity seen in drugs like prednisone. (D) Allergic reactions – Incorrect While allergic reactions to corticosteroids are possible, they are rare and not a major concern in long-term corticosteroid use. Corticosteroids are actually used to treat allergic and hypersensitivity reactions due to their strong anti-inflammatory properties.",
      "correct_choice_id": 287350,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55545,
      "choices": [
        {
          "id": 287354,
          "text": "Lactulose"
        },
        {
          "id": 287355,
          "text": "Rifaximin"
        },
        {
          "id": 287356,
          "text": "Neomycin"
        },
        {
          "id": 287357,
          "text": "Spironolactone"
        }
      ],
      "text": "A 60-year-old male with cirrhosis develops hepatic encephalopathy. Which of the following medications is most commonly used to help reduce ammonia levels in the blood?",
      "unique_key": "Q3629427",
      "question_audio": null,
      "question_video": null,
      "map_id": 34247688,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Lactulose. Lactulose is the first-line treatment for hepatic encephalopathy (HE), a condition caused by elevated ammonia levels in patients with liver cirrhosis. The damaged liver is unable to efficiently metabolize ammonia, leading to its accumulation in the blood and subsequent neurotoxic effects. Lactulose is a non-absorbable disaccharide that lowers ammonia levels through two key mechanisms: Colonic acidification: Lactulose is metabolized by gut bacteria into short-chain fatty acids, which acidify the colon. This traps ammonia (NH3) in its protonated form (NH4+), preventing its absorption into the bloodstream. Laxative effect: Lactulose increases stool frequency, promoting ammonia excretion via the feces. Due to these effects, lactulose reduces serum ammonia levels, improving mental status in hepatic encephalopathy. It is commonly administered orally or rectally (as an enema) in severe cases. Incorrect Options: (B) Rifaximin – Incorrect Rifaximin is an oral, non-absorbable antibiotic that reduces ammonia-producing gut bacteria. It is often used as an adjunct therapy for hepatic encephalopathy but is not the first-line treatment. Lactulose remains the primary treatment, with rifaximin typically added in recurrent or refractory cases. (C) Neomycin – Incorrect Like rifaximin, neomycin is an antibiotic that reduces ammonia-producing gut bacteria. However, it is less commonly used due to potential nephrotoxicity and ototoxicity. Rifaximin is preferred over neomycin due to fewer systemic side effects. (D) Spironolactone – Incorrect Spironolactone is a potassium-sparing diuretic used to manage ascites in cirrhosis, but it does not lower ammonia levels or treat hepatic encephalopathy. Its mechanism of action involves aldosterone antagonism, which helps reduce fluid retention in cirrhotic patients.",
      "correct_choice_id": 287354,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55546,
      "choices": [
        {
          "id": 287358,
          "text": "Nephrotoxicity"
        },
        {
          "id": 287359,
          "text": "Nausea"
        },
        {
          "id": 287360,
          "text": "Pancreatitis"
        },
        {
          "id": 287361,
          "text": "Myelosuppression"
        }
      ],
      "text": "A 35-year-old woman with a history of ulcerative colitis is being treated with mesalamine. Which of the following is a common side effect associated with this medication?",
      "unique_key": "Q1329365",
      "question_audio": null,
      "question_video": null,
      "map_id": 34279018,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Nausea. Mesalamine (5-aminosalicylic acid, 5-ASA) is a first-line therapy for ulcerative colitis (UC) due to its anti-inflammatory properties. It works by inhibiting prostaglandin and leukotriene synthesis, thereby reducing intestinal inflammation. Mesalamine is available in various formulations, including oral and rectal preparations. One of the most common side effects of mesalamine is nausea, which occurs due to its local irritation of the gastrointestinal (GI) tract. Other mild GI-related side effects include abdominal pain, diarrhea, and bloating. Patients are often advised to take the medication with food or switch to an extended-release formulation to reduce nausea. Explanation of Incorrect Options: (A) Nephrotoxicity – Incorrect Although mesalamine has been associated with rare cases of interstitial nephritis, nephrotoxicity is not a common side effect. Patients on long-term mesalamine therapy may require renal function monitoring (serum creatinine and urinalysis) to prevent potential kidney injury. (C) Pancreatitis – Incorrect Acute pancreatitis is a rare adverse effect of mesalamine, but it is not a common side effect. If a patient develops severe epigastric pain and elevated pancreatic enzymes, mesalamine should be discontinued immediately. (D) Myelosuppression – Incorrect Myelosuppression is not a typical side effect of mesalamine. However, a related drug, sulfasalazine, can cause bone marrow suppression due to its sulfapyridine component. Patients on sulfasalazine require regular complete blood count (CBC) monitoring, but this is not necessary for mesalamine unless other risk factors are present.",
      "correct_choice_id": 287359,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}